Otsuka Pharma Scandinavia AB - Aktuellt https://www.mynewsdesk.com/se/otsuka_pharma_scandinavia_ab Mynewsdesk RSS - pressmeddelanden, nyheter och blogginlägg. Otsuka Pharma Scandinavia AB - Aktuellt https://www.mynewsdesk.com/se/otsuka_pharma_scandinavia_ab https://www.mynewsdesk.com/assets/graphics/logos/logo-small-9892f98564f91864075bd14001f8470f2f9bf254729c37044b4b1ac9b0db6b40.png 128 23 sv 15 Dawnzera™ (donidalorsen) har beviljats marknadsföringsgodkännande inom Europeiska unionen för förebyggande av ärftligt angioödem. Wed, 21 Jan 2026 11:16:01 +0100 TILLKÄNNAGIVANDE ENDAST FÖR EUROPEISKA MEDICINSKA OCH FARMACEUTISKA HANDELSMEDIER OCH EUROPEISKA FINANSIELLA MEDIER Dawnzera™ (donidalorsen) har beviljats marknadsföringsgodkännande inom Europeiska unionen för förebyggande av ärftligt angioödem. https://www.mynewsdesk.com/se/otsuka_pharma_scandinavia_ab/pressreleases/dawnzera-donidalorsen-har-beviljats-marknadsfoeringsgodkaennande-inom-europeiska-unionen-foer-foerebyggande-av-aerftligt-angiooedem-3427139?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/otsuka_pharma_scandinavia_ab/pressreleases/dawnzera-donidalorsen-har-beviljats-marknadsfoeringsgodkaennande-inom-europeiska-unionen-foer-foerebyggande-av-aerftligt-angiooedem-3427139?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Otsuka Pharma Scandinavia AB Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin A Nephropathy (IgAN) Thu, 12 Jun 2025 13:09:38 +0200 ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin A Nephropathy (IgAN) https://www.mynewsdesk.com/se/otsuka_pharma_scandinavia_ab/pressreleases/otsuka-sibeprenlimab-phase-3-data-show-a-statistically-significant-and-clinically-meaningful-proteinuria-reduction-for-the-treatment-of-immunoglobulin-a-nephropathy-igan-3391313?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/otsuka_pharma_scandinavia_ab/pressreleases/otsuka-sibeprenlimab-phase-3-data-show-a-statistically-significant-and-clinically-meaningful-proteinuria-reduction-for-the-treatment-of-immunoglobulin-a-nephropathy-igan-3391313?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Otsuka Pharma Scandinavia AB